Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LBL-033 in Advanced Malignant Tumors
NCT05779163Phase 2Completed
- Sponsor
- Leads Biolabs
- Start
- Apr 2023
- Primary completion
- Apr 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, T-cell Engagers
- Countries
- 1
01
Overview
A Phase 2 trial of LBL-033 in cancer, sponsored by Leads Biolabs. Started Apr 2023; status: completed.
02
Drugs
LBL-033
03
Conditions
cancer
Beyond the preview
Go deeper on NCT05779163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05779163.